Jak používáme v České republice inhibitory tyrozinkinázy (TKI) po stanovení diagnózy u pacientů s NSCLC?

• Title in English: How tyrosine kinase inhibitors (TKI) are used for diagnosis of non-small cell lung cancer (NSCLC) in the Czech Rebuplic
• Authors: SKŘIČKOVÁ Jana; CHLOUPKOVÁ Renata; BORTLÍČEK Zbyněk; HEJDUK Karel; BRABEC Petr; DUŠEK Ladislav; PEŠEK M.; KOLEK V.; GRYGÁRKOVÁ I.; KOUBKOVÁ L.; ČERNOVSKÁ M.; TOMÍŠKOVÁ Marcela; ROUBEC J.; HAVEL L.; SALAJKA F.; HRNČIARIK M.; ZEMANOVÁ M.; ŠATÁNKOVÁ Monika; BENEJOVÁ Andrea; SIXTOVÁ D.; MAREL M.; KREJČÍ J.; OPÁLKA P.; ČOUPKOVÁ H.
• Year of publication: 2017
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: Three tyrosine kinase inhibitors are curently available in the Czech Republic to treat NSCLC patients with activating mutations in the EGFR gene. Characteristics (such as age, sex, smoking habit) of Czech patients treated with gefinitib (138), afatinib (102) and erlotinib (40) in the years 2013-2016 were compared. Apart from significantly lower performance status in the afatinib group, no other statistically significant differences were found.